U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07161388) titled 'Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China' on Sept. 05.
Brief Summary: This prospective, multicentre, observational study aims to assess the effectiveness and safety of durvalumab as consolidation treatment for patients with LS-SCLC who have not progressed following CRT in real-world setting.
Study Start Date: Oct. 15
Study Type: OBSERVATIONAL
Condition:
Limited Stage Small-Cell Lung Cancer
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca
Published by HT Digital Content Services with permission from Health Daily Digest....